LIMNW
Liminatus Pharma, Inc. Warrants
NASDAQ · Healthcare · Biotechnology · US
$0.06
+0.00%Aug 18, 2026, 20:01 UTC
Liminatus Pharma, Inc. announced a 1-for-50 reverse stock split of its common stock, approved by its board and stockholders at the 2026 Annual Meeting held on August 3, 2026.
Source:Aug 18, 2026, 00:00 UTC
Liminatus Pharma, Inc. received a notice from NASDAQ on 2026-08-12 that it is not in compliance with Listing Rule 5550(a)(2) regarding minimum bid price, and plans to implement a 1-for-50 reverse stock split.
Jul 6, 2026, 00:00 UTC
Liminatus Pharma, Inc. issued 11,188,729 shares of common stock and 158,881.1271 shares of newly designated Series A Non-Voting Convertible Preferred Stock in connection with its merger, exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Jun 30, 2026, 20:30 UTC
Liminatus Pharma amended its definitive merger agreement with InnocsAI to expand its oncology cell therapy pipeline.
Source:Jun 3, 2026, 12:30 UTC
Liminatus Pharma entered into a warrant exercise agreement with existing accredited investors to exercise outstanding warrants for $1.9 million in gross proceeds.
Source: